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Abstract: Due to a multiplicity of causes provoking traumatic brain injury (TBI), TBI is a highly
heterogeneous pathology, characterized by high mortality and disability rates. TBI is an acute
neurodegenerative event, potentially and unpredictably evolving into sub-chronic and chronic
neurodegenerative events, with transient or permanent neurologic, cognitive, and motor deficits,
for which no valid standardized therapies are available. A vast body of literature demonstrates that
TBI-induced oxidative/nitrosative stress is involved in the development of both acute and chronic
neurodegenerative disorders. Cellular defenses against this phenomenon are largely dependent
on low molecular weight antioxidants, most of which are consumed with diet or as nutraceutical
supplements. A large number of studies have evaluated the efficacy of antioxidant administration to
decrease TBI-associated damage in various animal TBI models and in a limited number of clinical
trials. Points of weakness of preclinical studies are represented by the large variability in the TBI
model adopted, in the antioxidant tested, in the timing, dosages, and routes of administration used,
and in the variety of molecular and/or neurocognitive parameters evaluated. The analysis of the
very few clinical studies does not allow strong conclusions to be drawn on the real effectiveness of
antioxidant administration to TBI patients. Standardizing TBI models and different experimental
conditions, as well as testing the efficacy of administration of a cocktail of antioxidants rather than only
one, should be mandatory. According to some promising clinical results, it appears that sports-related
concussion is probably the best type of TBI to test the benefits of antioxidant administration.
Keywords: traumatic brain injury; oxidative/nitrosative stress; low molecular weight antioxidants;
concussion
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1. Introduction
Traumatic brain injury (TBI) affects more than 10 million people worldwide each year, representing
30% to 40% of all injury-related mortalities and disabilities among all age groups, with enormous
social and economic impacts [1,2]. Epidemiological previsions until 2030 indicate a 2–3-times higher
incidence of patients suffering from TBI-related disabilities than those with neurological disabilities
from Alzheimer’s disease or cerebrovascular disorders. Despite recent advances in trauma research
and the ongoing efforts of collaborative multidisciplinary studies to tackle this problem and improve
patients’ outcomes, TBI still represents a major global health burden and public health challenge among
all ages in all countries regardless of the patient’s income level.
1.1. Definition/Classification
TBI results from the absorption by the cerebral tissue of part of the energy associated with
an external mechanical force, not necessarily acting directly to the head. This amount of energy
causes the derangement of a myriad of biochemical, metabolic, and molecular functions, deeply
affecting brain cell homeostasis and leading to temporary or permanent impairment of consciousness,
neurocognitive deficits, neuromotor disabilities, or psychological disturbances [3,4]. The extent to
which these mechanisms are damaged in TBI depends on the severity of the impact. There are various
systems and scales to assess the severity of TBI, the most commonly used is the Glasgow Coma Scale
(GCS) which classifies TBI into mild (GCS range 13–15), moderate (GCS range 9–12) and severe (GCS
range 3–8). The GCS is obtained by scoring specific clinical assessments, including eye opening, motor
and verbal responses [5] (Table 1).
Table 1. Traumatic brain injury (TBI) severity classification, according to the Glasgow Coma Scale (GCS).
The score for each patient is calculated by summing the points obtained in each set of neurological
examination. Therefore, the minimal value that a TBI patient may score is 3 (corresponding to comatose
severe TBI patients) and the maximal is 15 (corresponding to the mildest group of mild TBI patients).
Score Eye Opening (E) Verbal Response (V) Motor Response(M)
1 No eye-opening No verbal response No response
2 Eye-opening to pain Incoherent Extension to pain
3 Eye-opening to speech Inappropriate words Flexion to pain
4 Spontaneous eye-opening Confused conversation Withdrawal to pain
5 Oriented Localizes to pain
6 Follows commands
As shown in Figure 1, the majority of TBI patients (80%) sustain mild injuries [6], which have less
mortality rates compared to both moderate and severe injuries (30–40%) [7].
According to the available epidemiological data [1,6,8], men are more prone to sustain TBI, which
is caused, more than 50% of the time, by falls and road traffic accidents (Figure 2).
Unfortunately, an increasing number of severe TBIs occur during brawls, and this is often due to
gunshots, with very devastating consequences.
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Figure 1. Rates of traumatic brain injury (TBI) according to the severity classification based on the 
Glasgow Coma Scale (GCS) score. Of the total TBI, 80% are mild TBI. Of these, 20% are concussions; 
80% of all concussions are sports-related concussions. 
According to the available epidemiological data [1,6,8], men are more prone to sustain TBI, 
which is caused, more than 50% of the time, by falls and road traffic accidents (Figure 2).  
 
Figure 2. Classification of TBI patients in terms of rates and types of the most frequent events causing 
a traumatic head injury. Data refer to USA epidemiological data, which are currently the most 
accurate worldwide. 
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Figure 1. Rates of traumatic brain injury (TBI) according to the severity classification based on the
Glasgow Coma Scale (GCS) score. Of the total TBI, 80% are mild TBI. Of these, 20% are concussions;
80% of all concussions are sports-related concussions.
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Figure 2. Classification of TBI patients in terms of rates and types of the most frequent events causing
a traumatic head injury. Data refer to USA epidemiological data, which are currently the most
accurate worldwide.
1.2. Triage
After assessing the injury severity, pre-hospital management at the scene of TBI occurrence is
mainly conducted to maintain vital physiological functions of the patient (airway, breathing, circulation,
spinal stability) until their transfer to an emergency department [9,10]. In the emergency department,
clinicians assess the sustained injuries and continue the supportive treatment, often performing
conventional neuroradiological exams to scan the head (and cervical spine on occurrence) by using
computed tomography (CT) and/or magnetic resonance imaging (MRI). These initial interventions
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depend on the severity of TBI and the national/local guidelines. Neurosurgeons assess the surgical
need and establish the treatment approach and management plan [9,10].
1.3. Therapy
Due to the heterogeneity of TBI and limited knowledge of the underlying pathophysiological
mechanisms, there are no current standardized surgical and pharmacological treatments for TBI
patients. Despite their promising preclinical outcomes, many intervention strategies have failed to
demonstrate beneficial effects in randomized controlled trials so that TBI patients are still waiting for the
discovery of drugs capable of decreasing mortality and disability associated with this pathology [11].
The primary insult resulting from the application of mechanical force in TBI occurs immediately and
is inevitable. The amount of permanent damage due to sudden neuronal death and permanent loss
of cerebral tissue functions is also inevitable, so that all the efforts at this stage are to prevent the
primary injury from happening [12]. The secondary insult, involving biochemical and molecular
processes described in the next paragraph, may last for days, weeks, or months, and its damaging
activity might actively be decreased by proper therapies [12]. This secondary insult is characterized
by the release of excitatory neurotransmitters (glutamate, aspartate), glucose dysmetabolism with
mitochondrial dysfunction, and free radical overproduction. Final consequences are the activation of
different molecular pathways and inflammatory cascades, leading to cellular apoptosis and damage of
the blood–brain barrier (BBB) permeability [12].
As previously stated, treatments deeply vary because of the heterogeneity of TBI and the patient’s
response to therapy and it is almost impossible to establish standard approaches to be used in all TBI
patients. At present, the drugs most frequently administered are aimed at controlling intra-cranial
pressure (ICP) within normal levels (<22 mm Hg) [13], maintaining cerebral blood flow and decreasing
secondary injury associated damage [12]. A list of these drugs is summarized in Table 2 [10–14].
Table 2. Summary of the main drug treatments administered to stabilize clinical conditions of TBI
patients in emergency departments.
Class Treatment Drugs Mechanism of Action
Osmotic therapy Mannitol Hypertonic saline Decrease brain edema, improve cerebralblood flow and blood rheology
Antiepileptic drugs
Phenytoin, Phenobarbital,
Carbamazepine, Valproate,
Levetiracetam
Prevent seizures, especially during the
first week after injury thus preventing
rise in ICP
Sedative agents Barbiturate: PentobarbitalBenzodiazepine: Midazolam
Reduce neuronal activity, metabolic
brain requirements and ICP
Pharmacological paralysis Succinylcholine, Atracurium,Rocuronium
Prevents high intra-thoracic pressure
during mechanical ventilation which is
transmitted intra-cranially
Opioid analgesics Morphine, Fentanyl, Alfentanil Pain control via their action on neuronalopioid receptors
Acute neurosurgical intervention is often required in moderate to severe TBI patients to evacuate
hematoma, causing compression of the brain within the closed skull and leading to the rise of
intracranial pressure (ICP). TBI patients needing surgical intervention should be managed in centers
with appropriate neurosurgery staff and a neurosurgical intensive care unit (NICU) [10]. A frequent
medical intervention is aimed at avoiding the ICP raised by controlling ventilation in order to reduce
partial CO2 pressure, a potent vasodilator. In the case of brain edema, the intravenous infusion
of hyperosmolar agents is a common clinical practice targeted to improve the blood rheology and
cerebral blood flow (CBF) [10,12]. Moderate to severe TBI patients often undergo therapy to induce
pharmacological paralysis and sedation aimed at avoiding an increase in ICP and to reduce the
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metabolic energy requirements of the brain [10,12]. It is highly recommended that mildly injured TBI
patients, particularly those who score <15 on the GCS, even in the absence of gross clinical symptoms,
are admitted for neurological observation and conventional neuroradiological evaluation (CT scan,
MRI), in order to exclude the presence of subdural and/or subarachnoid hematomas [10].
2. TBI and Oxidative/Nitrosative Stress: A Rationale for Antioxidant-Based Therapies
As mentioned above, primary TBI injury is the damage occurring to the tissue (cerebral cells,
blood vessels) when part of the energy, associated with the mechanical force causing the injury, is
discharged against nerve and blood vessel cells. Secondary TBI injury refers to a cascade of biochemical
and molecular mechanisms triggered by the primary insult. These neurochemical changes start
immediately after impact, last for hours, days, or weeks depending on the injury severity, and may
culminate in cerebral cell death with a loss of neuronal functions. The secondary insult is characterized
by the imbalance of ionic homeostasis, release of excitatory neurotransmitters (glutamate, aspartate),
glucose dysmetabolism with mitochondrial dysfunction, and free radical overproduction. Final
consequences are the activation of different molecular pathways and inflammatory cascades, leading to
cellular apoptosis and damage of the BBB permeability [15]. The formation of reactive oxygen species
(ROS) and free radicals in brain tissue following TBI is well documented and plays a crucial role in
triggering molecular damaging processes (lipid peroxidation, DNA damage, protein oxidation) and in
exacerbating glutamate excitotoxicity, mitochondrial dysfunction, ionic dysregulation, and activation
of cellular proteases [16–18]. A schematic representation of secondary injury is illustrated in Figure 3.
Glutamate release is one of the main processes activated after TBI [19] that causes an influx of Ca2+
into neuronal cells via activation of NMDA receptors [20] and leads to an “early” calcium dysregulation.
This negatively impacts the main mitochondrial function, namely, the electron transport chain (ETC)
coupled with oxidative phosphorylation (OXPHOS) for energy production (ATP), thus leading to energy
imbalance [21,22] and contributing to increased ROS production [23] with documented post-traumatic
membrane lipid peroxidation [24] (Figure 4).
Dysfunctional mitochondria are also characterized by an imbalance of the mitochondrial
quality control network, regulating fusion, fission, and mitophagy. These processes, also known as
mitochondrial dynamics, are tightly controlled by a set of proteins selectively promoting fusion (optic
dominant atrophy 1, OPA1; mitofusin 1 and 2, MFN1 and MFN2), fission (mitochondrial fission protein
1, FIS1; dynamin-related protein 1, DRP1) or mitophagy (mitochondrial serine/threonine-protein
kinase, PINK1; parkin, PARK2). Moderate to severe TBI inhibit fusion and activate fission and
mitophagy, consequently decreasing both the total number of mitochondria and the number of
those properly functioning. In this light, it has been shown that the peptide SS-31, specifically
targeting the mitochondrial phospholipid cardiolipin and providing significant neuroprotection in a
variety of neurological diseases, plays a significant role as a potential agent to reduce TBI-mediated
mitochondrial dysfunction and oxidative/nitrosative stress [25]. Its pre-impact administration decreased
ROS-mediated damage, inhibited apoptosis, and improved mitochondrial biogenesis, thus providing
significant neuroprotection in experimental TBI in mice [25].
Among ROS, superoxide anion is the first to be produced after TBI by cerebral cells via different
mechanisms, such as the activation of phospholipases and the arachidonic acid cascade (cycloxygenase,
COX), the conversion of xanthine dehydrogenase to xanthine oxidase, and, mainly, the malfunctioning
of mitochondrial ETC [26]. Activated microglia and infiltrating neutrophils and macrophages also
provide additional sources of superoxide radical [27,28] at later time points after TBI, very frequently
through the activity of NADPH-oxidase (NOX) [29]. Oxidation of Fe2+ of extravasated hemoglobin
(Hb), as a result of the rupture of cerebral blood vessels, may also provide a further source of ROS.
Physiologically, superoxide anion is rapidly and efficiently converted into H2O2 + O2 by the enzyme
superoxide dismutase (SOD) [29], and H2O2 is then detoxified into O2 + H2O mainly by glutathione
peroxidase and, partly, by catalase and peroxiredoxins. Superoxide anion overproduction by the
aforementioned mechanisms, coupled with acidosis frequently occurring after TBI, favor H2O2 to
Antioxidants 2020, 9, 260 6 of 34
react with reduced iron of extravasated Hb, producing hydroxyl radicals through the Fenton reaction.
Hydroxyl radicals have no specific defense antioxidants, have a tremendously high oxido-reductive
potential, and can easily attack nearly any biological molecule capable of donating one electron and
causing its irreversible modification [26]. In addition, oxidized Fe3+ (either from extravasated Hb or
released from ferritin) contributes to the hydroxyl radical generation through the reaction of Fe3+ with
superoxide anions (the Haber–Weiss reaction) which regenerates Fe2+ for further Fenton reactions.
The high oxido-reductive potential allows hydroxyl radicals to tear off one H• from double bonds of
polyunsaturated membrane phospholipids, thus initiating the dangerous lipid peroxidation reaction
chain disrupting the functions and integrities of biological membranes [30].
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Figure 3. Schematic representation of some of the main pathological processes characterizing the
TBI-associated secondary insult. The force discharged and partly absorbed by the cerebral tissue at
the time of impact (primary insult) induces immediate glutamate release by neurons, change in the
blood–brain barrier (BBB) permeability, frequent hemorrhage, and decrease in the cerebral blood flow
(CBF). Excitotoxic phenomena due to sustained glutamate (Glu) release deeply alter ionic homeostasis,
particularly causing an increase in mitochondrial Ca2+. Malfunctioning of the mitochondrial electron
transport chain (ETC) and oxidative phosphorylation (OXPHOS) is consequent to increased Ca2+ entry
and decreased oxygen and glucose delivery (due to a decrease in CBF), and ultimately generating
decreased ATP formation with an energy crisis. Ca2+ also activates endothelial (eNOS) and neuronal
(nNOS) isoforms of nitric oxide (NO) synthase, promotes the conversion of xanthine dehydrogenase
(XDH) into xanthine oxidase (XO), and triggers the arachidonic acid cascade activating phospholipases.
The change in BBB permeability modifies water vascular permeability, causing vasogenic brain edema,
and allows infiltration and activation of macrophages/microglia, that are responsible either for NO
overproduction by the inducible NO synthase (iNOS) or for the release of pro-inflammatory cytokines.
Hematomas generate the release of hemoglobin (Hb) from ruptured erythrocytes and the consequent
oxidation of Fe2+ of Hb to Fe3+. This last process, together with XO activity, the arachidonic acid cascade,
activated macrophages/microglia, and dysfunctional mitochondria, generates a flow of superoxide
anion (O2•−) and gives rise to the reaction with NO and the formation of peroxynitrite (ONOO•−).
The damaging action of ROS and RNS on polyunsaturated fatty acids of phospholipids of biological
membranes triggers a lipid peroxidation reaction chain, culminating in neuronal cell death.
TBI also greatly affects the homeostasis of nitric oxide (NO). NO is a fundamental signaling
gaseous molecule in the nervous, immune, and cardiovascular systems, transmitting both intracellular
and intercellular signals crucial for cell and organ survival. It is produced by the activity of a family of
enzymes named nitric oxide synthases (NOS). The 3 NOS isoforms (endothelial, neuronal, and inducible)
are not equally upregulated after TBI [31–33]. Depending on which isoform is more upregulated, NO
may or may not exert beneficial effects. For example, although increased NO synthesis occurs early after
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TBI, the amount generated by nNOS and eNOS [33,34] has a crucial role as a vasodilator in maintaining
cerebral blood flow [35]. In contrast, NO formed intracellularly in cerebral cells by iNOS is deeply
involved in the generation of reactive nitrogen species (RNS) and in the so-called nitrosative stress
response [36]. The temporal coincidence of excess ROS and RNS production gives rise to the concomitant
insurgence of oxidative/nitrosative stress [37]. In particular, the reaction between NO radical and
superoxide anion (NO + O2•−) generates peroxynitrite (ONOO•−). Peroxynitrite decays into various
unstable RNS, as well as into nitrite and nitrate, which are considered the stable NO end-products.
Peroxynitrite and RNS actively take part in depleting cerebral antioxidant defences and in causing lipid
peroxidation of mitochondrial membranes [38], further deteriorating Ca2+ homeostasis [39], and in the
additional dysfunction of mitochondria through the formation of the membrane permeability transition
pore [40], in delaying normalization of ionic homeostasis [41], and in mediating calpain-catalyzed
proteolysis and neurodegeneration [42]. It is worth recalling that involvement of oxidative/nitrosative
stress has been addressed as a fundamental pathobiological mechanism of cerebral tissue injuries
occurring in numerous acute and chronic neurodegenerative disorders, affecting mitochondrial
functions, and appearing particularly relevant in the progression of chronic neurodegenerative
disorders (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis) [43–45].
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characterizing the TBI-mediated sec ndary i sult. ETC and OXPHOS are impaired by the increase
in Ca2+ and the change in the mito hond ial q ality control (MCQ) network. A ecreas in fusion
(OPA1, MFN1, MFN2) and an increase i fission (DRP1, FIS1) and mitophagy (PINK1, PARK2) greatly
contribute to the reduced mitocho d i l phosphorylating capacity, u balanced ATP production and
consumpti , leading to an energy crisis. C comitantly, an insurgen e of oxidative/nitrosative
stress takes pl ce due to the overproduction f ROS and RNS exceedi g the cell antioxidant defenses.
The intrinsic pathway of apoptosis vi cytochrom c r lease and caspase activation leads to increasing
cerebral cell death.
By definition, an insurgence of oxidative/nitrosative stress takes place anytime cells/tissues/organs
undergo an imbal nce between ROS and RNS formation and their respectiv antioxidant defe ses.
In addition to enzymes capable to scavenging ROS (SOD, catalase, glutathion p roxidase, heme
oxygenase, thioredoxin), cells are protected from oxidativ /nitrosative stress by low molecular weight
antioxidants [46], particularly when considering protection from certain ROS (hydroxyl radicals)
and RNS (peroxynitrite). A schematic representation of the main sources of ROS and RNS during
oxidative/nitrosative stress occurring after TBI is shown in Figure 5.
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Figure 5. Schematic representation of the main sources of ROS and RNS during oxidative/nitrosative
stress occurring after TBI. The severity of injury is quite well correlated with high or low
oxidative/nitrosative stress and with protraction of intra- and extracellular ROS and RNS generation
from the various potential sources. For instance, mild TBI rarely causes hematomas with hemoglobin
extravasation and mobilization of ferritin iron, thus strongly decreasing the amount of iron used in
the Haber–Weiss-sustained Fenton reaction. Conversely, severe TBI induces long-lasting conditions
of metabolic derangement due to mitochondrial dysfunction. A vicious cycle is formed between
the increased energy requirement, either to satisfy repairing processes or to counteract dangerous
phenomena (glutamate excitotoxicity, ionic homeostatic disequilibrium), and the damaging molecules
originating from mitochondrial ETC unable to manage the tetravalent reduction of molecular oxygen
to water minimizing superoxide formation.
In general, the common characteristic of these defense molecules is their remarkable reducing
power that renders them highly “attractive” nearly for any type of oxidant, including ROS and RNS.
A gross division into hydrophilic (water-soluble) and hydrophobic (fat-soluble) antioxidants clusters
them into water-rich (cytoplasm, mitochondrial matrix) and fat-rich (biological membranes) cell
compartments, thereby determining, and/or limiting, their possibility to interact with ROS and RNS
(Figure 6).
With the exclusion of reduced glutathione (GSH), uric acid, and coenzyme Q10 (these last two are
secondary antioxidants since this is not their primary biological role), another common characteristic
of low molecular weight antioxidants is that mammals are unable to perform their synthesis so that
they depend on regular intake with diet to have adequate circulating and tissue concentrations of
antioxidants [47]. Therefore, the quality of food consumed and/or supplementation of adjuvants and
nutraceuticals is of fundamental importance in order to provide significant protection in the case of
increased ROS and RNS formation [48,49]. Although the link between oxidative/nitrosative damage
and TBI is evident and the awareness that deficiency in antioxidant-rich foods in the daily diet may
further exacerbate TBI symptoms is highly plausible, there are still no clear evidence of successful
antioxidant therapies in the clinical setting [50], despite a continuous growth of studies, reporting either
preclinical or clinical data, using supplementation with natural or synthetic low molecular weight
antioxidants, that have appeared in the literature in the last decades as potentially useful treatments
in TBI [18,51]. This tendency is certainly due to different reasons, including the lack of standardized,
clearly effective pharmacological approaches of TBI patients, the increased knowledge of the molecular
mechanisms underlying cerebral damage after TBI, and the lack of unwanted side effects for the large
majority of low molecular weight antioxidants.
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therapy to TBI patients. Their respective chemical properties localize the components of the two
categories into hydrophilic (cytoplasm, mitochondrial matrix) or hydrophobic compartments (biological
membranes), therefore characterizing the potential antioxidant activities of the different compounds.
In this review, we analyze data from the literature concerning the use of antioxidants in the
post-injury period to alleviate the effects of TBI, considering either preclinical or clinical studies, with
no limitations in terms of severity of TBI patients, experimental TBI models, animal species, routes
of antioxidant administration, doses of antioxidant tested, parameters evaluated, but limiting our
search only to those compounds having a well-established and direct antioxidant activity towards ROS
and/or RNS.
3. Low Molecular Weight Antioxidants in TBI: Summary of Preclinical and Clinical Studies
3.1. Ascorbic Acid (Vitamin C)
Ascorbic acid (AA) is o e of the most abundant water-soluble antioxidants within mammalian
tissues, acting as a reducing cofactor in sev ral enzymati reactio s [52]. Being a powerful reducing
agen , it q ickly reacts, thr ugh ne or t o electron reactions, with a wide ange of ROS and RNS,
including p roxynitrite and hydroxyl radic ls. AA is involved in the recycling of oxidized -tocopherol
(Vitamin E) contributing to the maintenance of -tocopherol redox state within biological membranes,
and its deficiency is associated with impairments in conn ctive tissue integrity. Since AA is not
synthesized by most mammals (including human beings), the body depends on vitamin C-rich food
ingestion to satisfy its AA need [53]. Efficient absorption of this molecule mainly occurs through
the SVCT1 Na+-ascorbic acid transporter activity [54,55]. Although, circulating levels of AA are
relatively low (30 to 70 mol/L serum in healthy humans) [47], abundant AA concentrations are found
in peripheral tissues, particularly in the brain, where it is usually present in concentrations up to
3000 mol/L brain water [56–58]. The SVCT2 Na+-ascorbic acid transporter, ubiquitously distributed
on the cell membrane of the different tissues, provides the electrogenic AA transport exploiting the
favorable extracellular/intracellular sodium gradient [59,60]. Although AA is one of the most studied
free radical scavengers and is particularly abundant in the brain, only one preclinical and one clinical
study have examined the effects of AA in TBI, even though it has been shown that the level of AA
in the cerebral tissue decreases rapidly following experimental TBI [56,61]. Its depletion is strictly
dependent on the severity of the injury, remaining well below control values even longer after severe
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TBI and returning to pre-impact concentrations after 72 h in mildly injured animals [21,62]. In a
model of closed-head TBI, animals received pre-treatment with different doses of AA (intraperitoneal
administration of 45 or 60 mg/kg/die) for two weeks, alone or in combination with equal dosages
of -tocopherol, that was administrated for an additional 2 weeks after impact [62,63]. Results of this
study indicate that AA, even if administered alone, reduced mortality rate, decreased cerebral tissue
and circulating levels of malondialdehyde (MDA), restored brain values of AA, and stimulated tissue
superoxide dismutase levels [64].
In a double blind controlled clinical trial, Razmkon et al. [65] divided a cohort of 100 TBI patients
into four groups receiving either a low dose of AA (500 mg/die i.v. for 7 days), or a high dose of AA
(10 g i.v. on admission and 4 days after, followed by 4 g/die i.v. for the remaining 3 days), or vitamin
E (400 IU/die i.m. for 7 days), or placebo. Beneficial effects of high dosage of this antioxidant were
observed in AA-treated patients who showed decreased progression of perilesional edema on CT scan.
The relatively modest effects of AA recorded in this study might be due to the malfunction of the
SVCT2 transporter that normally ensures the electrogenic AA transport into cells. Potentially, the ionic
imbalance typically encountered following TBI might perturb the functioning of the AA transporter,
thus limiting the effectiveness of AA-based therapy. It might also be possible that decreased expression
of SVCT2 occurs following TBI.
3.2. N-Acetyl-Cysteine
GSH is one of the low molecular weight antioxidants that mammals are able to synthesize [66].
Since the -SH group of GSH is supplied by cysteine, high levels of this amino acid are essential to
ensure adequate GSH tissue levels. Due to the fundamental role of GSH in detoxifying reactions, both
to scavenge ROS and RNS and to eliminate xenobiotics, increased cysteine availability is needed under
conditions of oxidative/nitrosative stress. GSH functions as an essential antioxidant, as well as the most
important reducing agent for protein –SH groups, and it has recently been demonstrated to be involved
in the modulation of inflammatory processes [67]. It is the cofactor of the enzymes GSH peroxidases
(GPx) and glutathione-S-transferases. The reduction of oxidized GSH (GSSG) is performed by the
NADPH-dependent enzyme GSH reductase (GR), responsible for the maintenance of high values of the
GSH/GSSG ratio. The brain is highly rich in GSH (3000 mol/L brain water), where it has been shown
that GSH binds to the glutamate NMDA and AMPA receptors, possibly acting as an endogenous
neuromodulators [68,69]. Additionally, GSH operates as an activating agent of ionotropic receptors,
thus suggesting even a role of GSH in cerebral neurotransmission [70]. It is worth underlining that
part of the total GSH cellular content is under the form of the stable S-nitrosoglutahione (GSNO)
deriving from the interaction of NO with GSH. GSNO is considered a reservoir of intracellular NO, a
transducer of the NO signaling, and an antioxidant due to its ability to break the lipid peroxidation
reaction chain. GSNO levels are regulated by the NADH-dependent activity of GSNO-reductase,
deeply involved in the regulation of protein nitrosylation and secondary formation of RNS [71]. Hence,
maintaining high levels of GSH allows the formation of adequate concentrations of GSNO. Several
experimental studies have observed a decrease in brain GSH following TBI. Among these, Ansari et al.
showed a significant decrease of GSH/GSSG from 3 to 96 h post-TBI in rat hippocampus, which was
mirrored by a time-dependent decline of GPx and GR activities [72]. It was reported that concentrations
of rat brain GSH significantly declined depending on the severity of injury in a model of graded
diffuse TBI [56]. Whilst in mild TBI (mTBI), a spontaneous recovery late post-injury was observed,
severely injured animals had a permanent decrease of brain GSH up to a week following TBI [56]. In
addition, a decrease of GSH in CSF of children who suffered a severe TBI has also been reported [73].
Similarly, lower levels of cysteine and glycine, both fundamental for the GSH biosynthesis, were also
demonstrated after mild and severe TBI [74]. Interestingly, it has been demonstrated that the i.p.
administration of 150 mg/kg γ-glutamylcysteine ethyl ester (GCEE), approximately 10 min postinjury,
produced a significant decrease of oxidative/nitrosative damage to proteins following TBI in the
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rat [75], thus supporting the rationale of applying therapies aimed at increasing cerebral GSH of the
post-injured brain.
The aforementioned results motivated the use of N-acetylcysteine (NAC) as a potential new
treatment in TBI, either acting as a direct ROS and RNS scavenger, or operating by improving the
availability of cysteine and ultimately enhancing GSH synthesis. Since these NAC effects have been
well documented in both preclinical and clinical studies, various authors evaluated the benefits of
NAC administration in experimental models of TBI, as well as its administration in TBI patients.
The potential of GSH precursors as treatment options for TBI has been summarized in a recent review
by Koza et al. [76]. In a model of contusion cortical impact, administration of a single dose of NAC
(150 mg/kg) 15 min after injury decreased MDA formation, increased SOD and GPx, and protected
morphology and the number of neurons of rats sacrificed at 2 and 12 h post-TBI [77]. NAC was
also used in combination with minocycline (MINO) and administered 12 h after injury. NAC +
MINO prevented the TBI-induced decrease in the expression of oligodendrocyte antigenic markers
CC1, 2′,3′-cyclic-nucleotide 3′-phosphodiesterase, and phospholipid protein between 2 and 14 days
post-CHI [78]. These results indicated an ample therapeutic window of NAC administration justifying
the potential clinical application of NAC in the treatment of TBI patients. In a different study, 150 mg/kg
NAC was orally administered (via gastric gavage) at 1, 24, 48, and 72 h after mild closed-head TBI.
Results showed that NAC decreased plasma lipid peroxidation and IL-1b levels, increased brain cortex
IL-4, GSH, TAS, vitamin A, AA and -tocopherol values, and increased erythrocyte GSHPx levels [79].
3.3. Flavonoids
Flavonoids are a class of more than 5000 naturally occurring compounds, largely present in plants
and fungi [80]. Their common structure is formed by one phenyl ring fused with an oxygen-containing
heterocyclic ring to which is linked a second phenyl ring. Since, in the different flavonoids, the number
of –OH groups is higher than one, flavonoids are more generally termed as polyhydroxy polyphenols,
or simply polyphenols. Chemically, they are divided into three groups: flavonoids or bioflavonoids,
isoflavonoids, and neoflavonoids. Flavonoids are divided into five sub-groups (anthocyanidins,
anthoxanthins, flavanones, flavanonols, and flavans), isoflavonoids into five sub-groups (isoflavones,
isoflavonones, isoflavans, pterocarpans, rotenoid), and neoflavonoids into two sub-groups (neoflavones
and neoflavenes). The large majority of all the aforementioned compounds are water-soluble, and,
it is assumed, they are consumed in variable proportions, with foods of vegetal origin, according
to the different dietary habits. The common characteristic of flavonoids is that they possess a very
negative oxido-reductive potential, therefore acting as powerful antioxidants towards any type of ROS
and RNS [81]. A growing number of preclinical studies have investigated the effects of flavonoid
administration in reducing TBI-associated damage, the results of which have been condensed into
Table A1 of Appendix A.
Given the wide interest in the assessment of natural compounds (including flavonoids) obtained
from a variety of vegetable sources and the large number of flavonoids, it is difficult to find two studies
examining the same flavonoid, and it is therefore difficult to directly compare studies investigating the
effectiveness of flavonoid-based therapies.
In a small pilot clinical trial, 60 patients who experienced mild TBI and showing symptoms from
3 to 12 months after injury, received oral enzogenol (1 g/die) for 6 weeks. Cognitive functioning
before and after treatment was investigated. Compliance, side-effects, cognitive failures, working and
episodic memory, post-concussive symptoms, and mood were assessed at baseline, 6, 12, and 16 weeks.
Patients receiving enzogenol were found to have significantly fewer self-reported cognitive failures
than those in the placebo group [82].
3.4. Resveratrol
Resveratrol is an antioxidant with modest, but significant, solubility in water and good solubility
in organic solvents, thus indicating its prevalent hydrophobic nature. It is formed by two 6-carbon
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aromatic rings (one with two and the other with one -OH groups) linked by a C=C bridge and allowing
the existence of cis- and trans-resveratrol. This form of polyphenol is abundantly present in the skin of
red grapes. However, red wines are the food source with the highest resveratrol levels. High resveratrol
intake, due to high red wine ingestion, was originally suggested as one of the possible explanation of
the so-called “French paradox” concerning the apparently low occurrence of cardiovascular diseases in
the French population, in spite of a high fat (mostly saturated) diet consumption [83]. Apart from its
intrinsic antioxidant activity, resveratrol seems to modulate several cell functions, including defense
mechanisms, mitochondrial functions, and inflammatory processes [84].
A preclinical study in rats evaluated the effects of a single dose of resveratrol (100 mg/kg)
administered intraperitoneally immediately after TBI induced by the weight-drop model. Brain water
content and levels of MDA, GSH, NO, and xanthine oxidase (XO) were evaluated at 24 h after impact.
In the resveratrol-treated group, significantly lower values of MDA, XO and NO, and increased level
of GSH were observed. Additionally, resveratrol treatment also attenuated tissue lesion area [85].
Another study analyzed the protective effect of resveratrol in TBI in vivo and in vitro. Results showed
that cell death after TBI is induced through the ROS/GSK-3β/mitochondria signaling pathway and
that administration of resveratrol (100 mg/kg) immediately after controlled cortical impact (CCI)–TBI
can increase cell survival by suppressing GSK-3β-mediated autophagy and apoptosis [86]. In one
additional study, mice were treated with either placebo or resveratrol (100 mg/kg) at 5 min and 12 h after
induction of mild TBI using CCI. In comparison to placebo-receiving animals, results demonstrated
a reduction of microglial activation in the brain regions of the cortex, corpus callosum, and dentate
gyrus induced by mild TBI in resveratrol treated rats. In addition, resveratrol decreased IL-6 and IL-12
expressions suggesting a general decrease of neuroinflammation caused by TBI [87].
3.5. α-Tocopherol (Vitamin E)
Tocopherols are a family of fat-soluble compounds, found in high concentrations in various vegetal
oils, having a remarkable antioxidant capacity. Tocopherol congeners having vitamin E activity are four
tocopherols and four tocotrienols, the former having a saturated hydrocarbon harbored side chain, the
latter having an unsaturated hydrocarbon harbored side chain composed by three isoprene units [88,89].
The chromane ring, to which the hydrocarbon chain is bound, is the oxido-reductive center common to
all the eight compounds. Its single OH-group can easily lose one electron, in the form of a hydrogen
radical, under the action of highly oxidizing ROS and RNS and forming the corresponding, relatively
stable, tocopheryl- or tocotrienyl-radical. The hydrophobic side chain of tocopherols allows these
compounds to localize within the phospholipid bilayer of biological membranes, where they act as
interrupters of lipid peroxidation chain reactions. When oxidized by ROS and RNS, tocopheryl-radicals
strictly depend on AA availability to get recycled into their respective fully reduced forms. Among
the eight congeners, -tocopherol is the most abundant in the European diet and -tocopherol in the
American diet. Albeit the brain is rich in easily oxidizable fat-soluble compounds, mainly found in
the biological membrane structures of the nerve cells, it is one of the mammalian tissues with the
lowest content of tocopherols. This renders the brain potentially more exposed to lipid peroxidation
phenomena mediated by oxidative/nitrosative stress.
As in the case of AA, several animal studies using different TBI models at different severities
have been conducted, but only one clinical study evaluated the effects of -tocopherol administration
to TBI patients. In guinea pigs experiencing mild or severe TBI, Inci et al. found that -tocopherol
(100 mg/kg), intraperitoneally administered before graded TBI, decreased brain levels of MDA derived
from oxidative/nitrosative stress-mediated lipid peroxidation. The authors concluded that -tocopherol
administered early post-injury is beneficial to decrease tissue damage associated with TBI [90]. In a
model of focal moderate TBI, Sprague–Dawley rats received a daily intraperitoneal injection of
-tocopherol (600 mg/kg), subsequently to TBI induction. At different times post-impact, neurocognitive
tasks, histochemical evaluation of tissue damage, and expressions of Nogo-A and NgR, two protein
factors inhibiting nervous cell regeneration, were evaluated in all animals. Results showed that rats
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treated with -tocopherol performed better on neurocognitive tests, had less evident histological signs of
edema, inflammation, and necrosis, as well as decreased expression of Nogo-A and NgR. The authors
proposed that -tocopherol may reduce ROS-mediated tissue damage and promote cerebral tissue
regeneration following TBI [91]. In a model of focal moderate TBI, the effects of administration of
tocopheryl-succinate (100 mg/kg) + polyethylene glycol (PEG) (2 mL/kg), injected 30 min before or
5 min after injury, were evaluated in rats subjected to fluid percussion. Although PEG alone improved
the parameters under evaluation, the combination tocopheryl-succinate (100 mg/kg) + PEG (2mL/kg)
showed the best increase in the survival rates and the best improvement of neurocognitive tasks
and motor function, suggesting that this type of infusion might be effective in the clinical setting
to decrease TBI-associated damage [92]. Aiguo et al. fed rats using a regular diet with or without
500 IU/kg of -tocopherol for 4 weeks, at the end of which animals received focal mild TBI, according
to the fluid percussion injury model [93]. It was shown that the -tocopherol-rich diet prevented
TBI-increased oxidative damage to proteins, the decrease in SOD, Sir2, and BDNF caused by TBI, and
improved TBI-associated motor function impairments. The authors’ conclusions were that dietary
-tocopherol supplementation could decrease the damaging effects of mild TBI on synaptic plasticity
and cognitive functions.
Despite the beneficial effects of -tocopherol in preclinical studies, translation to the clinical setting
was only performed in the previously cited Razmkon study [65]. Among the four groups of TBI
patients, those who were administered -tocopherol (400 IU/die intramuscularly for 7 days) showed a
significant reduction of mortality rates and improvement of long-term functional outcomes.
3.6. Coenzyme Q10
Coenzyme Q (ubiquinone) is a fat-soluble compound ubiquitously found as a component of the
mitochondrial electron transport chain in oxygen-dependent living organisms. It is characterized by
a quinone ring which, through oxido-reductive reactions exchanging one or two electrons, allows
coenzyme Q to exist in a fully oxidized, fully reduced, or semi-reduced (semi-quinone radical) form.
Depending on the organism considered, the quinone ring is bound to a hydrophobic chain, made up of
isoprene units, repeated from a minimum of 3 to a maximum of 10 units (as it occurs in humans). This
last form of coenzyme Q, named coenzyme Q10 (CoQ10), is found in the mitochondrial inner membrane
actively participating in the transfer of electrons from Complex I and Complex II to Complex III, where
the so-called CoQ10 cycle takes place [94].
Several studies were performed, testing the effects of exogenously administered CoQ10 under
various pathological conditions to counteract oxidative/nitrosative stress, ameliorate mitochondrial
dysfunction, and decrease inflammatory processes [95]. The rationale was attributed to the CoQ10
oxido-reductive potential, by its ability to affect one-electron transfer reactions by forming the
semi-quinone radical, by the relatively long-living, low reactivity of its semi-quinone radical and by its
high hydrophobicity clustering CoQ10 within biological membranes. It should, however, be recalled
that the main CoQ10 biological role is that of ensuring the electron transfer through ETC and not that of
acting as an antioxidant [96]. However, very recently, it has been shown that CoQ10 interacts with FSP1
acting as a novel plasma membrane oxidoreductase and protecting cells from glutathione-independent
ferroptosis [97].
At present, few animal studies have evaluated the role of CoQ10 administration in the treatment of
head trauma, with no clinical studies conducted to date. In the Marmarou model of moderate diffused
closed-head TBI, CoQ10 was administered at a dose of 10 mg/kg immediately after trauma and after
24 h by gavage. Compared to trauma only, this treatment decreased MDA levels, vascular congestion,
neuronal loss, nuclear pyknosis, nuclear hyperchromasia, cytoplasmic eosinophilia and axonal edema,
and increased cerebral SOD [98]. In rats receiving TBI according to CCI, administration of CoQ10
immediately after impact was found to significantly affect the cerebral expression of genes involved in
mechanisms of bioenergetics and oxidative/nitrosative stress [99]. The same research group tested the
effects of intra-arterial CoQ10 infusion before or 30 min after TBI induced by CCI [100]. Results indicated
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a decrease in brain mitochondrial damage and apoptosis, as well as lower circulating values of two
markers of TBI severity, namely, serum glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal
hydrolase-L1 (UCH-L1). However, in this study, in vivo MRS (magnetic resonance spectroscopy) failed
to show any significant amelioration of neurometabolism produced by CoQ10 treatment [100].
3.7. Carotenoids
Carotenoids are a class of pigments synthesized by plants, algae, and photosynthetic bacteria [101],
composed of 8 isoprene units with a total of 40 carbon atoms. There are over 1100 known carotenoids,
which are categorized into a class of carotenoids containing oxygen (xanthophylls) and a class of
oxygen-free, purely hydrocarbon carotenoids (carotenes). In the human brain, various carotenoids,
including -carotene, -carotene, -carotene, -cryptoxanthin, lutein, and zeaxanthin, can generally be
measured [102]. Some of them (-carotene, -carotene, -carotene, -cryptoxanthin) can be converted into
vitamin A and are therefore directly involved in the mechanism of vision, ensuring adequate retinol
formation. Since the different carotenoids are distributed into a variety of foods mainly of vegetal origin
(fishes and crustaceans, such as salmon and red shrimps, derive their high carotenoid level on the high
intake of carotenoid-containing algae), their daily ingestion, and therefore their relative amount within
tissues, is strictly dependent on the individual dietary regimen, as well as on the supplementation
of carotenoid-containing adjuvants or nutraceuticals. In general, carotenoids exhibit antioxidants
and anti-inflammatory properties, as well as possess modulatory activities of autophagy. The use
of various carotenoids as potential treatments for several pathologies, including neurodegenerative
diseases, have been extensively studied [102].
In a stretch injury model of TBI using astrocyte cultures, astaxanthin attenuated apoptosis by
inhibiting NKCC1 expression, and reduced the expression of NF-κB-mediated pro-inflammatory
factors [103]. In mice, intraperitoneal injection of astaxanthin (10, 25, 50, or 100 mg/kg body weight)
administrated 30 min after impact, decreased TBI-related brain tissue injury (induced by CCI) by
dose-dependently ameliorating AQP4/NKCC1-mediated cerebral edema. In addition, the highest dose
examined was shown to improve neurologic deficits and the BBB permeability [104]. In a different
study, astaxanthin (25 or 75 mg/kg) was administered to mice via oral gavage beginning 30 min
post-trauma and followed by six additional daily oral gavages. Animals received a left frontal TBI
using a weight-drop device. Results showed that astaxanthin administration improved sensorimotor
performance and enhanced cognitive recovery. In addition, reduction of lesion size in the cortex and
expressions comparable to controls of brain-derived neurotrophic factor (BDNF), growth-associated
protein-43 (GAP-43), synapsin, and synaptophysin (SYP), indicating the induction of neuronal survival
and plasticity, were recorded [105].
Many other carotenoids have been investigated in TBI animal models, and molecular mechanisms
have also been described. Among these, fucoxanthin showed neuroprotective effects via regulation of
the Nrf2-ARE and Nrf2-autophagy pathways [106]. Bexarotene inhibited apoptosis and inflammation
by upregulating the lncRNA Neat1 [107], and improved the neurological functions of mice after
TBI, partially through apolipoprotein E [108]. Administration of crocin has shown neuroprotective
effects partially dependent on the activation of Notch signalling [109]. Lastly, lutein, another strong
antioxidant with anti-inflammatory and anti-apoptotic effects, and capable of crossing the BBB, showed
protective effects by suppressing interleukin IL 1β, IL 6, and monocyte chemoattractant protein
1 expressions [110].
3.8. Omega-3 Fatty Acids
Omega-3 fatty acids are a group of polyunsaturated fatty acids (PUFA) that have three (linolenic
acid) to six (docosohexaenoic acid) double bonds in their carbon chain of 18 (linolenic acid) to 22
(docosohexaenoic acid) carbon atoms in length. Considering their last carbon atom as the -atom, this
group of PUFA has the common characteristic of one double bond positioned on the third carbon
atom far from the -atom. Omega-3 fatty acids are either essential (linolenic acid) or semi-essential
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(eicosapentaenoic acid, docosahexaenoic acid) for humans. Our body is unable to synthesize linolenic
acid (the precursor of the other omega-3 fatty acids) that should be ingested in adequate amounts with
diet. However, humans are capable of providing little but significant amounts of docosahexaenoic
acid (DHA) and eicosapentaenoic acid (EPA) from the elongation and desaturation of linolenic acid,
through a specific metabolic pathway. Omega-3 fatty acids are not only fundamental components
of membrane phospholipids but also precursors of other important biologically active molecules
(prostaglandins). Particularly DHA and EPA are abundantly found in the brain phospholipids, with
the former representing about 50% of the weight of the neural tissue cell membranes [111]. Although
real benefits in patients with neurodegenerative disorders are still controversial, the supplementation
of omega-3 fatty acids has been tested in various pathologies characterized by increased ROS and
RNS production. The rationale is either in the pure antioxidant activity of omega-3 fatty acids or in
the possibility that an aliquot of those exogenously administered might help in restoring biological
membranes damaged by oxidative/nitrosative stress-mediated lipid peroxidation.
In Table A2 of Appendix A, we summarize key preclinical studies evaluating the role of omega-3
fatty acids and DHA in TBI and examined more detailed clinical studies carried out in TBI patients.
It is worth underlining that the three clinical studies available in the literature do not support the
results reported in experimental TBI.
Matsouoka et al. [112] evaluated the effects of the combined daily administration for 12 weeks of
1470 mg DHA and 147 mg EPA to a group of 53 traumatized patients, 52% of which suffered from mild
TBI. A control group of 20/57 traumatized subjects sustained mild TBI and was administered with
placebos. Outcome measures were posttraumatic stress disorder (PTSD) symptoms, assessed by the
Clinician-Administered PTSD Scale, and depressive symptoms, assessed by the Montgomery–Åsberg
Depression Rating Scale, both evaluated at baseline and after 12-weeks, together with the serum levels
of mature BDNF and precursor pro-BDNF. Results showed no effect of DHA + EPA on PTSD, depressive
symptoms, or serum BDNF levels, thus confuting the efficacy of these omega-3 in ameliorating mental
status of patients sustaining mild TBI [109]. Same authors reported no effects of the combined daily
administration for 12 weeks of 1470 mg DHA and 147 mg EPA, even if enriched with 0.3% a-tocopherol,
when the same patients were fully evaluated for the post-injury quality of life. Also in this case, the
authors concluded that the administration of omega-3, specifically DHA and EPA, is not justified by
their clinical results to treat TBI patients [113]. The last study showed a clinical case of an elderly
patient taking warfarin and fish oil supplementation (rich in omega-3 fatty acids) after suffering blunt
head trauma and who manifested an irreversible fatal warfarin-induced coagulopathy. This study,
although reporting only one case, reveals the risks of omega-3 fatty acid supplementation in patients
taking anticoagulant medications, because of the synergistic effect of the two treatments (warfarin and
omega-3 fatty acids) in inhibiting platelet aggregation promoting untreatable bleeding [114].
4. Discussion
Concussion is a traumatically induced transient perturbation of brain functions occurring at any
time impacts of different intensities, not necessarily hitting the head, cause an acceleration–deceleration
phenomena of the skull [115,116]. The most dangerous impacts are those inducing rotational and
translational movements of the head. Very commonly, and erroneously, the term concussion is
interchangeably used with mild TBI. Therefore, it is certainly true that all concussions are mTBIs,
and it is equally true that not all mTBIs are concussions [117]. Concussions are characterized by
a rapid onset of spontaneously resolving clinical symptoms, typically represented by neurological
impairment and cognitive deficits. Since during a concussive event part of the energy associated to the
impact is also discharged towards the cerebral tissue, concussion is known to trigger a plethora of
biochemical, metabolic, and molecular changes transiently, but deeply, altering cerebral cell functions
and homeostasis. This complex pathobiological process is also known as the neurometabolic cascade of
concussion [117–119]. The concussed brain is characterized by transient alteration of ionic homeostasis,
imbalanced cellular calcium exchange and storage, which leads to mitochondrial dysfunction with an
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energy crisis. Glucose dysmetabolism [120], alteration of the mitochondrial quality control [121,122],
impairment of cell energy state [121–123], and increase of ROS and RNS production [124] characterize
a temporal window following concussion during which the brain is “metabolically vulnerable” It
has been clearly demonstrated that alterations of brain metabolism last much longer than symptom
disappearance and return of neurocognitive functions to pre-impact levels. A second concussive event
of even lesser magnitude than the first, falling within this period of vulnerability, may have catastrophic
consequences causing a clinical condition termed as second impact syndrome (SIS). When occurring,
SIS is fatally characterized by untreatable malignant cerebral edema associated with high disability and
mortality rates. Repeat concussions, taking place before complete restoration of neurometabolism, may
be the basis of the degeneration into chronic traumatic encephalopathy (CTE). CTE has been described
in retired athletes who sustained a high number of concussions (mainly unreported) in their career [125],
and it is a progressive neurodegenerative disorder causing a dramatic loss of neurocognitive functions
and evolving into dementia [125,126].
Concussions represent about 20% of all mTBI. Of all concussions, 80% are sports-related
concussions. Athletes, particularly those practicing sports characterized by frequent physical contact
(such as boxing, martial arts, American football, ice hockey), are at much higher risks of concussions
than non-athletes. Amateur and non-athletes suffer the influence of post-concussive symptoms
in their everyday life as the main consequences connected to concussions. In contrast, the main
problems for semi-professional and professional athletes refer to the time they are forced to stay out
of the competitions, before their return to play following a concussion. According to what is stated
above, sports-related concussions are a type of TBI in which prevention might effectively be applied
either by modifying rules of those sports disciplines at higher risk of concussion, or in preventively
treating athletes with drugs capable of inhibiting specific molecular pathways activated by concussions.
It should also be taken into account that drug treatments might be helpful in allowing safer return
of athletes to play. In this light, few studies have been carried out to evaluate the effects of the
administration of antioxidants prior to concussion in reducing molecular changes and symptoms
associated with concussion [127].
Antioxidant Therapies in Sports-Related Concussion
In a clinical study evaluating the effect of enzogenol administration, 42 athletes with a history of
sports-related concussion in the chronic phase of injury were enrolled. Athletes sustained concussions
from 0.5 to 3 years prior to the start of the study and 28/42 of them experienced repeat concussions.
They were blindly and randomly divided into two groups, one receiving placebos and the other 1 g/die
of enzogenol. Both treatments were administrated for six weeks. Athletes were assessed on recruitment
and at the end of drug administration, using virtual reality (VR), electroencephalography (EEG), and
neuropsychological (NP) tasks. The enzogenol-treated group showed enhanced frontal-midline theta
and decreased parietal theta power, indicating reduced mental fatigue compared to the placebo group.
Subjects enrolled in the enzogenol group also self-reported reduced mental fatigue and sleep problems.
The authors concluded that enzogenol has the potential to improve brain functioning in the chronic
phase of concussion [128].
In a study evaluating the prophylactic effects of DHA administration, 81 American football athletes
were recruited, and blindly and randomly administered with 2, 4, and 6 g/die of DHA or placebo.
During the 189 days of the study duration, blood of athletes was analyzed at various times (coincident
with changes in intensity, hours of contact, and likely changes in head impacts) neurofilament light
(NFL) serum levels, as an indicator of axonal injury. The main finding was that DHA likely attenuates
the increase in serum NFL, suggesting a neuroprotective effect of DHA towards a central pathogenic
mechanism of concussion (axonal injury). Interestingly, the lowest dose (2 g/die) appeared to produce
the most marked decrease in serum NFL levels [127].
Although it did not refer to sports-related concussions, one clinical trial (NCT00822263), carried
out to test the efficacy of NAC on symptoms associated with blast exposure mild TBI (causing the same
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symptoms as concussion) in a Southwest Asia combat setting, is certainly worth being mentioned.
In this prospective study, 81 symptomatic U.S. service members who were exposed to a blast wave or
who were in a vehicle that was damaged by a blast wave, and who met the criteria for concussive mild
TBI (balance dysfunction, confusion, headache, sensorineural hearing loss, impaired memory, and sleep
disturbances), accepted to participate in the study. Randomly assigned patients received either placebo
or 4-g loading dose of NAC followed by 4 g daily (in two divided doses of 2 gm morning and night)
for 4 days and then by 3 gm daily (in two divided doses of 1.5 gm morning and night). Treatments
started in a variable time ranging 24–72 h from blast exposure. When compared to placebo, results
showed beneficial effects of oral NAC administration on neuropsychological test results, number of
TBI symptoms, and full symptom resolution on day seven, following the beginning of treatment. Early
initiation of NAC administration was also found to have additional benefit on the neurological but not
on neuropsychological outcome measures [126].
5. Conclusions
The analysis of the literature concerning the beneficial effects of antioxidant-based therapies to
reduce TBI-associated damage leads to the following indications: (i) there are no sufficient clinical
data to determine whether adding the administration of antioxidants to that of drugs commonly
used in TBI patients improves outcome in terms of decreased mortality and disability; (ii) for the
majority of both water- and fat-soluble antioxidants, clinical studies are completely lacking; (iii) data
from experimental TBI in laboratory animals are supportive of beneficial effects of administration of
antioxidants in TBI of any severity; (iv) clear effectiveness of antioxidants, dosages, timing and route
of administration, biochemical and molecular parameters, clinical and neurological parameters have
not yet been established, rendering less strong the indications reported in these preclinical studies;
(v) there are no data in the literature, either clinical or preclinical, for natural antioxidants (lycopene,
anthocyanins) commonly found in a balanced diet, such as the Mediterranean diet.
It is our opinion that it will be very difficult to obtain conclusive evidence showing that antioxidant
administration to TBI patients is truly beneficial. In the past, preclinical studies demonstrated that ROS
generation [129] and ROS-mediated damage [130,131] take place in the very early phase following TBI.
Furthermore, a clinical study, in which TBI patients were analyzed for CSF content of antioxidants
and ROS-mediated lipid peroxidation biomarkers within 3 h from injury, clearly showed that all
TBI patients reached the NICUs, having dramatic ascorbate decrease and evident MDA increase in
their CSF samples [132], i.e., most of ROS- and RNS-mediated damage was already completed at the
time of potential antioxidant administration. Altogether, the aforementioned preclinical and clinical
findings indicate a very narrow therapeutic window to allow antioxidant therapies to have a reasonable
probability of having positive effects. It is also our opinion that it should be much more effective to
test, either in animals or in human beings, the administration of a cocktail of antioxidants, distributing
in different cell compartments, having differential ROS and RNS scavenging activity and performing
secondary activations of different pathways beneficial for the post-injured brain, rather than expecting
resounding ameliorations using the administration of one antioxidant only.
One further crucial observation is that, in the case of TBI, it is not feasible to attempt preventive
medicine based on the administration of antioxidants, since there is no chance to know whether one
will sustain TBI during his life span. Differently, preventive administration of antioxidants might
be performed in sports-related concussion. By initially selecting those athletes practicing sports
at high risk of concussion (any contact and some non-contact sports), it might certainly be easy to
demonstrate whether athletes treated with antioxidants and who experienced a concussion have less
concussion-associated symptoms, cognitive deficits, and neurometabolic alterations, as well as having
shorter recovery periods than control, placebo-treated, concussed athletes. Therefore, it appears quite
evident that sports-related concussion and athletes have the best chance of representing the preferential
TBI type and patient population to evaluate future antioxidant therapies in humans.
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Abbreviations
AA Ascorbic Acid
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AQP4 Aquaporin-4
BBB Blood–Brain Barrier
BDNF Brain-Derived Neurotrophic Factor
CBF Cerebral Blood Flow
CBV Cerebral Blood Volume
CCI Controlled Cortical Impact
COX Cyclooxygenase
CSF Cerebro-Spinal Fluid
CT Computed Tomography
CTE Chronic Traumatic Encephalopathy
DHA Docosohexaenoic Acid
DHE Dihydroethidium Staining
DRP1 Dynamin-Related Protein 1
EEG Electroencephalography
eNOS Endothelial Nitric Oxide Synthase
EPA Eicosapentaenoic Acid
ETC Electron Transfer Chain
FIS1 Fission Protein 1, mitochondrial
FJB/C Fluoro Jade B or C staining
FST Forced Swimming Test
FPI Fluid Percussion Injury
GAP-43 Growth-Associated Protein-43
GCS Glasgow Coma Scale
GFAP Glial Fibrillary Acidic Protein
GPx Glutathione Peroxidases
GSH Reduced Glutathione
GSK-3β Glycogen Synthase Kinase 3 Beta
GSNA Greater Splanchnic Nerve Activity
GSNO Nitrosoglutathione
GR GSH Reductase
GSSG Oxidized Glutathione
Hb Haemoglobin
H&E Hematoxylin and Eosin staining rotocol
ICH Immunohistochemistry
ICP Intracranial Pressure
IL Interleukin
iNOS Inducible Nitric Oxide Synthase
i.m. Intramuscular
i.v. Intravenous
lncRNA Neat1 Long noncoding RNA nuclear enriched abundant transcript 1
MDA Malondialdehyde
MFN1 or 2 Mitofusin 1 or 2
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MINO Minocycline
mNSS Modified Neurological Severity Score
mTBI Mild Traumatic Brain Injury
MWM Morris Water Maze
NAC N-Acetylcystein
NFL Neurofilament Light
NF-κB Nuclear Factor kappa-light-chain-enhancer of activated B cells
NICUs Neurosurgical Intensive Care Units
NKCC Sodium–potassium–chloride cotransporter
NMDA N-Methyl-D-Aspartate
nNOS Neuronal Nitric Oxide Synthase
NO Nitric oxide
NOR Novel Object Recognition
NOS Nitric Oxide Synthases
NOX NADPH Oxidase
NP Neuropsychological
Nrf2-ARE Nuclear factor E2-related factor 2 Antioxidant Response Elements
NSS Neurological Soft Signs
OPA1 Optic dominant Atrophy 1
OXPHOS Oxidative Phosphorylation
PARK2 Parkin
PAT Passive Avoidance Task
PEG Polyethylene Glycol
PINK1 mitochondrial serine/threonine-protein kinase 1
PTSD Posttraumatic Stress Disorder
PUFA Polyunsaturated Fatty Acids
RNS Reactive Nitrogen Species
ROS Reactive Oxygen Species
SIS Second Impact Syndrome
SOD Superoxide Dismutase
SVCT1 or 2 Sodium dependent vitamin C transporter 1 or 2
SYP Synaptophysin
TAC Total Antioxidant Capacity
TBARS Thiobarbituric Acid Reactive Substance
TBI Traumatic Brain Injury
TEM Transmission Electron Microscopy
TST Tail Suspension Test
TUNEL Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling assay
UCH-L1 Ubiquitin Carboxy-terminal Hydrolase-L1
VCS Veterinary Coma Scale
VR Virtual Reality
WB Western Blot
WD Weight Drop
XO Xanthine Oxidase
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Appendix A
Table A1. Summary of preclinical studies on flavonoid administration in different models of TBI.
Name of Flavonoid Dosage and Route ofAdministration Time Points Tests and Assays TBI Model Main Findings Ref
Chrysin
25, 50, or 100 mg/kg orally,
started immediately
post-injury and continued for
up to 3 or 14 days
1 day before injury; 0, 1, 4
h, and 1, 2, 3, 4, 7, 13, 14,
28 days post-injury
VCS, rotarod test, PAT,
biochemical assay,
histochemical staining,
TUNEL, IHC
WD
Chrysin enhanced post-injury motor
function, cognitive status and neuronal
loss via reduction of oxidative stress
(increased concentrations of SOD, CAT,
GPx, GSH, and decreased MDA level)
and inhibition of the apoptotic proteins
(decreased Bax and increased Bcl-2) in
the cerebral cortex and CA3
hippocampal neurons
[133]
Wogonin
1, 2.5, 5 mg/kg. (i.v.) before and
after moderate TBI;
Alternatively, 2 µL (10 mM)
injected into the lateral cerebral
ventricle (i.c.v.) before and
after moderate TBI
Before injury and 0.5, 1, 2,
4 h post-injury
Arterial pressure, heart rate,
baroreflex and GSNA,
histochemical staining of
hippocampus
FPI
Wogonin administered before or after
TBI significantly improved the
cardiovascular changes (MAP, HR, and
baroreflex) occurring after FPI.
[134]
Isoliquiritigenin (ILG) 20 mg/kg (i.p.) 1 h post-TBI 1 and 7 days after TBI
Sensorimotor Garcia test,
brain water content, BBB
permeability assay,
histochemical staining, cell
viability assay, WB, RT–qPCR,
fluorescence immunoassays
CCI
ILG improved neurologic functions by
reducing brain edema, BBB permeability,
apoptosis (decrease in expression of
cleaved caspase 3), and oxidative stress
(translocation of Nrf2 into the nucleus
with activation of downstream proteins).
[135]
Hesperidin 50 mg/kg orally from day 10 to24 post-injury Day 21 and 24 post-injury
Sucrose preference test, FST,
suppressed feeding test, TST,
biochemical analysis
WD
Hesperidin reduced depression
symptoms, levels of IL-1β, TNF-α and
MDA, and increased BDNF levels in the
hippocampus
[136]
Icariin
Oral administration of 3, 10, 30
mg/kg on injury induction and
daily for 7 days post-injury
0, 3, 7, 8 days post-TBI
Rotarod test, balance beam
test, Y-maze, WB, IHC,
histochemical staining,
protein expression
Modified CCI
Icariin improved sensory motor and
cognitive functions, and upregulated
BDNF, SYP, and PSD-95 after injury.
However, no improvement of brain
histology and neuronal death were
found.
[137]
Baicalin 50, 100, 150 mg/kg (i.p.) 30 minafter TBI
2 h, and 1 and 3 days
post-TBI
NSS, brain water content,
TUNEL assay, WB
Immunostaining, RT-qPCR
WD
Baicalin improved neurological function,
brain edema, apoptosis, and oxidative
stress via activating the Akt/Nrf2
pathways
[138]
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Formononetin
Intragastrical administration of
10, 30 mg/kg/die for up to 7
days after TBI
7 days post-injury
ELISA of tissue and serum
cytokines, Cytohistologic
stains, RT-qPCR, WB
WD
Formononetin counteracted TBI-induced
neuroinflammation by decreasing tissue
and serum levels of IL-6 and BDNF, and
increasing tissue and serum levels IL-10
[139]
Troxerutin 1.5 mL/kg (i.p.) for 5 daysbefore TBI 3 days post-injury
NSS, MRI, ELISA, Nissl,
TEM, WB and
Immunostaining
WD
Troxerutin improved neurovascular
function and integrity post-injury
through action on eNOS and NO level,
with consequent decrease in
peroxynitrite formation
[140]
Quercetin 50 mg/kg (i.p.) at 30 min, 12 hand 24 h post-TBI 1, 3, 5 days post-injury
Brain water content, NSS,
H&E staining and neuron
count, IHC, WB
WD
Reduced brain edema, neural apoptosis
and improved motor function (inhibition
of extracellular signal-regulated kinase
1/2 phosphorylation and activated Akt
serine/threonine protein kinase
phosphorylation)
[141]
Resveratrol
0.05, 0.1 mg/kg via oral gavage
for 10 consecutive days, 7 days
after TBI
7 days post-injury MWM, WB, TAC, Apoptosis,DHE staining CCI
Reduced cognitive deficits, ROS
generation, and apoptosis after TBI via
recovered activation of p38/Nrf2/HO1
signaling pathway
[142]
Silymarin 50 mg/kg via gavage for 20days before injury
8–10, 11, 18–20, 21
post-injury
Open field, elevated
plus-maze, light-dark box,
elevated zero-maze, sucrose
preference, FST, TST, TNF-α
WD
Decreased anxiety and depression-like
behaviours after injury due to reduced
TNF-α levels in the prefrontal cortex and
hippocampus
[143]
Diosmin 100 mg/kg (p.o.) for 7 daysbefore TBI
–1 h, 1 h, 1,2,15days
post-injury
VCS, passive avoidance
memory, BBB permeability,
brain edema, ELISA
WD
Protective effects against TBI-induced
memory and long-term potentiation
impairment through reduction of TNF-α
concentration in hippocampus
[144]
Catechin 1, 5, 10, 20 or 30 mg/kg daily viagavage up to 28 days post-TBI
3, 5, 7, 14, 21, 28 days
pot-injury
Brain infarct volume edema,
foot-fault test, MWM, BBB
permeability, RT-qPCR, WB
CCI
Catechin prevented tight junction
disruption and preserved BBB integrity,
reducing post-injury inflammatory
reaction
[145]
7,8-dihydroxyflavone
5 mg/kg (i.p) post-TBI either
had access to voluntary wheel
running for 7 days after injury
or were sedentary
7, 14 days post-injury
Barnes maze, voluntary
running wheel exercise, WB,
rsfMRI
FPI
7,8-DHF enhanced the levels of cell
energy metabolism (COII, PGC-1α,
AMPK) and hippocampal functional
connectivity
[146]
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Pycnogenol 50, 100 mg/kg (i.p.) 15 min, 3 h,6 h post-TBI 2, 5, 7, 12 days post-injury
MWM, FJB, cortical tissue
sparing CCI
No improvement of cognitive ability
post-injury in MWM maze task.
Pycnogenol suppressed NO through the
inhibition of iNOS and also the
NF-kB/AP-1 pathway.
[147]
Breviscapine 50 mg/kg (i.v.) post-TBI 1, 4, 7, 14, 21 dayspost-injury
NSS, RT-PCR, WB, IHC,
Immunostaining, TUNEL WD
Neurobehavioral function improved
after treatment due to GSK3β signaling
pathway inhibition
[148]
Hydroxysafflor
yellow A 10, 30 mg/kg orally post-TBI 6 h, 12 h, 24 h post-TBI
Detection of HSYA, SOD,
MDA, CAT, GSH/ GSSG CCI
HSYA reduced oxidative stress by
improving the activities of SOD and
CAT, the level of GSH, and the
GSH/GSSG ratio. Additionally, it
decreased the levels of MDA and GSSG
[149]
Genistein 15 mg/kg (i.p.) 30 min andagain 24 h after TBI –1, 1, 2 days post-TBI
Brain oedema, BBB
permeability, ICP, VCS,
beam-walk task
WD
Genistein inhibited brain edema, BBB
permeability, and improved ICP after
TBI. It also improved neurobehavioral
performance and motor disorder
[150]
Epicatechin
5, 15, 45 mg/kg by gavage at 3 h
after TBI and once daily for 3
days or 15 mg/kg EC at 3 h
after TBI and then once daily
for 7 days
1, 2, 3, 7, 14, 21, 28 days
post-TBI
Neurologic deficit score,
forelimb placing test,
wire-hanging test, rotarod
test, TST, FST, sucrose
preference test, IHC, brain
water content, Hb, WB,
Immunostaining
CCI
EC significantly reduced lesion volume,
edema, and cell death and improved
neurologic function on days 3 and 28.
Cognitive performance and
depression-like behaviors were also
improved by activating the Nrf2
pathway, inhibiting heme oxygenase-1
protein expression, and reducing iron
deposition
[151]
Procyanidins 100 mg/kg (i.v.) PC within30 min post-TBI
24 h, and 11, 12, 13, 14
days post-injury
MWM, MDA, GSH, SOD,
ELISA, WB CCI
Procyanidins improved cognitive
performance by reducing the level of
MDA, increasing GSH and activity of
SOD, elevating the levels of BDNF,
phosphorylation-cAMP-response
element-binding protein (pCREB), total
CREB, and cyclic AMP (cAMP)
[152]
Proanthocyanidin Not mentioned 72 h post-injury
Cerebral water content,
TBARS, nitrite and nitrate,
Thiols
Cold injury
Proanthocyanidin attenuated oxidative
and nitrosative stress and decreased
brain edema
[153]
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(–)-epigallocatechin
gallate (EGCG)
0.1% (w/v) EGCG pre- and
post-TBI. Solution was
prepared by dissolving the
drug in drinking water
1, 3, and 7 days post-TBI
MWM, IHC, immunostaining
for ssDNA and NeuN, lipid
peroxidation
CCI
EGCG treatments improved cognitive
impairment through inhibiting free
radical-mediated neuronal degeneration
and apoptotic cell death around the area
damaged by TBI.
[154]
Puerarin 200 mg/kg (i.p.) before injury 24 h post-injury
WB, MDA, GSH,
Naþ-Kþ-ATPase activity,
Myeloperoxidase activity,
FJC
WD
Puerarin ameliorated oxidative
neurodegeneration after TBI through the
activation of PI3K-Akt pathway
[155]
Luteolin
In vivo
10, 30, 50 (i.p.) mg/kg post-TBI
In vitro
5, 10, and 25 µM post-TBI
1, 3, 7 days post-TBI
Grip test, brain water content,
MDA, GPx activity, TUNEL,
IHC, WB, nuclear extraction
and electrophoresis mobility
shift assay, RT-qPCR, cell
viability
WD
Luteolin enhanced the translocation of
Nrf2 to the nucleus both in vivo and
in vitro, upregulation of heme
oxygenase 1 (HO1) and
NAD(P)H:quinone oxidoreductase 1
(NQO1). Luteolin neuroprotective
effects are possibly mediated by the
activation of the Nrf2–ARE pathway
[156]
Naringin
100 mg/kg orally
7 days before and
7 days after the TBI
7 days post-injury
NSS, brain water content,
serum and tissue biochemical
analysis, WB
WD
Naringin improved behavioral
dysfunction by attenuating the increases
in MDA and NO; enhancing the
activation of SOD; decreasing the
over-activation of iNOS;
down-regulating the overexpression of
IL-1b; and reducing the brain edema.
[157]
Baicalein
30 mg/kg (i.p.) immediately
following injury or daily for 4
dayspost-injury
Before injury, 1, 4, 7, 14,
21 days after injury
Rotarod test, y test, mNSS,
beam walk test, RT-PCR, WB,
IHC, ELISA, FJB
CCI
Baicalein attenuated the contusion’s site
expression of TNF-α, IL-1β and IL-6
mRNA and cytokine protein.
[158]
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Table A2. Summary of preclinical studies on omega-3 fatty acids administration in different models of TBI.
Dosage and Route of Administration Time Points Tests and Assays TBI Model Main Findings Ref
DHA: 500 nmol/kg (i.v.) 30 min
post-injury 7, 28 days post-injury mNSS, MRI, ICH CCI
Reduced lesion size, microglia, and astrocytic
reactivity, decreased the accumulation of
beta-amyloid precursor protein (APP) at 7 days
post-TBI. Reduced the neurofilament light (NFL)
levels in plasma at 28 days.
[159]
DHA: 7.5 mg/100 mL (i.p.) 30 min after
TBI 1, 3, 7, 14 days post-injury
Brain nitrates and nitrites (NOx),
NOR, markers of microglial
activation, astrocyte marker, mRNA
of inflammation-related genes
CCI
Decreased oxidative stress at day 1 and
pro-inflammatory microglial activation at day 3.
Decreased oxidative stress, histologic damage, and
mRNA markers of microglial pro-inflammatory
activation. Improved short term cognitive function.
[160]
NPD 1:50 ng intra-lesionally,
immediately following TBI 1,3 days post-injury
FJB, TUNEL, Immuno-staining and
lesion size analyses PBI NPD1 decreased the lesion area at 72 h [161]
DHA: 370, 550, 740 mg/kg/day,
intragastric administration 30 min after
TBI.
1, 4, 7, 14, 21 days post-injury NSS, MWM TUNEL, Nrf2-AREpathway-related genes FPI
Improved neuromotor and cognitive functions,
increased anti-apoptotic protein expression, SOD
and GPx activity, translocation of Nrf2 to the
nucleus. Increased the expression of the
downstream factors NAD(P)H:quinone
oxidoreductase (NQO-1) and HO-1.
Neuroprotective potentially mediated through
activating the Nrf2- ARE pathway.
[162]
DHA: 16 mg/kg (i.p) at 30 min, 1, 3, 5
days after TBI 1, 2, 3, 4, 5 days post-injury
NSS, beam walking test and rotarod
test, qRT-PCR, WB, TUNEL, IHC CCI
Improved neurological and cognitive functions.
Decreased apoptosis, TLR4 expression, and the
expression of inflammatory mediator NF-Kappa B.
[163]
DHA: 370, 740 mg/kg/day (i.v.)
30 min after TBI and daily for 15 days 2, 7 and 15 days post-injury Beam-walking, MWM, RT-qPCR FPI
Protection against motor deficits. Inhibition of
caspase-3 upregulating the Bcl-2:Bax ratio. [164]
Resveratrol 50 mg/L via drinking water;
Omega3 fatty acids and prebiotics were
administered via powdered food (100 g
of prebiotic, 300 g of DHA, and 600 g of
standard diet per 10 kg of food) for 43
days before TBI.
43–60 days
Neurological test battery,
expression of Aqp4, Gfap, Igf1, Nfl,
Sirt1, and Tau genes
Focal closed- head
Treatment altered the behavioral performance and
prevented injury-related deficits in the longer-term
behavior measures, Decreased expression of Aqp4,
Gfap, Igf1, Nfl, and Sirt1in the prefrontal cortex.
[165]
DHA: 16 mg/kg (i.p.) at 5 min, 3 to 21
days, after TBI 3, 7, 21 days post-injury
Activation of microglia or
macrophages, inflammatory
response, neurons expression of the
endoplasmic reticulum (ER) stress
marker CHOP
CCI
DHA administration reduced neuronal ER stress
and subsequent association with microglial or
macrophage polarization after TBI. Potential
amelioration of TBI-induced cellular pathology
[166]
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DHA: 0.1% diet. 1 d before TBI and for
50 days after TBI
1, 2, 3, 12, 28, 41, 47, 50 days
post-injury
Inflammatory cytokines, nitrates,
and nitrites, MWM, T2-weighted
MRI, diffusion tensor imaging,
histological exams
CCI Decreased cognitive impairment, oxidative stress,and white matter injury in adult rats [167]
ω-3 PUFA: 2 mL/kg (i.p.) 30 min after
TBI and daily for 7 days 1, 3, 7 days post-injury
mNSS, brain water content, NISSl
staining, microglial activation,
immunofluorescent staining, WB,
TLR4/NF-κB
Feeney DM TBI model
ω-3 PUFA supplementation inhibited TBI-induced
microglial activation and the subsequent
inflammatory response by regulating HMGB1
nuclear translocation and secretion and also
HMGB1-mediated activation of the TLR4/NF-κB
signaling pathway, leading to neuroprotective
effects.
[168]
DHA: 16 mg/kg (i.p.) 15 min after the
injury and daily for 3 or 7 days. 3, 7 days post-injury.
RT–qPCR, immunoblotting,
immunostaining, DTI, MWM CCI
DHA administration restored hippocampal
lysosomal biogenesis and function, demonstrating
its therapeutic potential.
[169]
Diet containing 10% corn oil with a fatty
acid profile high inω-6 PUFAs and low
inω-3 PUFAs for 3 days before injury
3, 6, 12 h
Two-photon laser scanning
microscopy (2PLSM), parenchymal
cell death and reactive oxidative
species (ROS), (GSH),
neuroprotectin D1 (NPD1)
Closed-head
Neuroprotection by decreasing cell death, ROS
formation, and preserving GSH and NPD1
expression.
[170]
DHA (1.2%) enriched diets and/or
curcumin (500 ppm) for 2 weeks
post-injury
1, 2, 3, 4, 5 days and 2 weeks Cognitive tests, WB, markers oflipid peroxidation FPI
DHA alone or in combination improved cognitive
functions, decreased oxidative stress and damage to
membrane phospholipids. Curcumin
complemented the action of DHA on TBI pathology
[171]
DHA = 1.2% of diet coupled with
exercise for 12 days 12 days
Expression of acyl-CoA oxidase 1
(Acox1), 17β-hydroxysteroid
dehydrogenase type 4 (17β-HSD4),
calcium-independent
phospholipases A2 (iPLA2),
syntaxin-3 (STX-3), and BDNF
FPI
DHA activity was synergistic with exercise. The
effects were evident on restoration of membrane
homeostasis after TBI, thus supporting synaptic
plasticity and cognition.
[172]
Control diet: unhydrogenated soybean
oil (70 g/kg). Deficient diet: safflower oil
(66.5 g/kg) and soybean oil (3.5 g/kg).
1, 7, 14, 21, and 28 days after TBI
Ccl2, Gfap, and Mmp 9 mRNA
levels, MMP-2 and -9 enzymatic
activities, lesion volume
CCI
Decreased brain DHA content in TBI rats fed with
deficient diet contributed to poorer sensorimotor
outcomes after TBI through a mechanism involving
modulation of Timp1 expression.
[173]
DHA: 3, 12, 40 mg/kg diet for 30 days
prior TBI 1 week after injury WMW, IHC WD
Dietary supplementation with DHA increased DHA
serum levels, reduced TBI-associated tissue damage
(axonal injury counts, markers for cellular injury
and apoptosis), and improved memory assessment
by the water maze testing.
[174]
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